Nab-Paclitaxel + Cisplatin + Gemcitabine in Untreated Metastatic Pancreatic Adenocarcinoma

Model scores of the 29,894 trials active now.

Model score 20% for any early termination, 9% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,198 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2023-01-23. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: prior topatients mustradiationulndefined
  Phrases that lowered it: malelesionsgemcitabinefemaleefficacy
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Maximum age: 105 (lowers risk) · Who can join
• Sponsor's past termination rate: no earlier finished trials (lowers risk) · Sponsor's track record
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 4 (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Number of arms: 1 (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports with a death: 21.9% (raises risk) · Drug's FDA history
• Drug's FAERS reports marked serious: 95.3% (raises risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Collaborators: 1 (raises risk) · Design
• Sponsor's past trials: 0 (raises risk) · Sponsor's track record
• Blinding: none (raises risk) · Design
• Has a data monitoring committee: No (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• First-line Treatment of Metastatic Pancreatic Cancer With Nab-paclitaxel and Gemcitabine NCT02564146 · started 2016 · scored riskier than 64% of active trials completed
• Nab-Pac+Cis+Gem in Pts w Previously Untreated Metastatic PDA NCT01893801 · started 2013 · scored riskier than 77% of active trials completed
• Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients NCT01461915 · started 2011 · scored riskier than 31% of active trials terminated
• First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma. NCT01964287 · started 2013 · scored riskier than 79% of active trials completed
• Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer) NCT01881230 · started 2013 · scored riskier than 85% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.